Drug
Crovalimab
Crovalimab: highest development phase Phase 3, developed by Roche. 5 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Roche
Trials
| Drug | Phase | Indication |
|---|---|---|
| Crovalimab NCT04654468 | Phase 3 | Paroxysmal Nocturnal Hemoglobinuria |
| Crovalimab NCT04432584 | Phase 3 | Paroxysmal Nocturnal Hemoglobinuria |
| Crovalimab NCT04958265 | Phase 3 | Atypical Hemolytic Uremic Syndrome |
| Crovalimab NCT04434092 | Phase 3 | Paroxysmal Nocturnal Hemoglobinuria |
| Crovalimab NCT04861259 | Phase 3 | Atypical Hemolytic Uremic Syndrome |
Latest
No recent events.
Follow Crovalimab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.